Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 is distinct from bortezomib (Velcade) and, importantly, triggers apoptosis in multiple myeloma (MM) cells resistant to bortezomib. Here we demonstrate that combining NPI-0052 and lenalidomide (Revlimid) induces synergistic anti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Chauhan, Dharminder, Singh, Ajita V., Ciccarelli, Bryan, Richardson, Paul G., Palladino, Michael A., Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2010
Assuntos:
Lymphoid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815518/
https://ncbi.nlm.nih.gov/pubmed/19965674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-03-213009
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares